Equities analysts expect Diplomat Pharmacy, Inc. (NYSE:DPLO) to post sales of $1.17 billion for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have made estimates for Diplomat Pharmacy’s earnings. The lowest sales estimate is $1.14 billion and the highest is $1.20 billion. Diplomat Pharmacy posted sales of $1.14 billion during the same quarter last year, which would indicate a positive year over year growth rate of 2.6%. The business is scheduled to announce its next earnings results on Tuesday, February 27th.

On average, analysts expect that Diplomat Pharmacy will report full year sales of $1.17 billion for the current financial year, with estimates ranging from $4.47 billion to $4.53 billion. For the next fiscal year, analysts forecast that the business will report sales of $5.40 billion per share, with estimates ranging from $4.97 billion to $5.74 billion. Zacks’ sales calculations are an average based on a survey of analysts that that provide coverage for Diplomat Pharmacy.

Diplomat Pharmacy (NYSE:DPLO) last posted its earnings results on Monday, November 6th. The company reported $0.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.10. Diplomat Pharmacy had a net margin of 0.18% and a return on equity of 8.30%. The firm had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.16 billion. During the same period in the previous year, the business posted $0.21 EPS. The business’s revenue was down 4.8% compared to the same quarter last year.

A number of equities analysts have weighed in on DPLO shares. BidaskClub cut shares of Diplomat Pharmacy from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 17th. Needham & Company LLC upped their price objective on shares of Diplomat Pharmacy from $23.75 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, November 8th. Robert W. Baird restated a “buy” rating and set a $20.00 price objective on shares of Diplomat Pharmacy in a research report on Sunday, September 17th. Deutsche Bank initiated coverage on shares of Diplomat Pharmacy in a research report on Monday, December 4th. They set a “buy” rating and a $22.00 price objective for the company. Finally, Mizuho set a $16.00 target price on shares of Diplomat Pharmacy and gave the company a “hold” rating in a research report on Tuesday, October 24th. Five equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. Diplomat Pharmacy presently has an average rating of “Buy” and a consensus target price of $20.72.

Diplomat Pharmacy (NYSE:DPLO) traded down $0.44 during trading hours on Friday, reaching $19.82. 654,400 shares of the company’s stock were exchanged, compared to its average volume of 805,757. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.34 and a quick ratio of 0.82. The firm has a market capitalization of $1,395.37, a PE ratio of 26.31, a PEG ratio of 3.65 and a beta of 0.61. Diplomat Pharmacy has a 52 week low of $12.25 and a 52 week high of $21.99.

In other Diplomat Pharmacy news, Director Jeffrey G. Park acquired 3,000 shares of the stock in a transaction dated Monday, November 20th. The stock was acquired at an average price of $15.46 per share, with a total value of $46,380.00. Following the completion of the purchase, the director now owns 7,640 shares in the company, valued at approximately $118,114.40. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Atul Kavthekar acquired 2,000 shares of the stock in a transaction dated Monday, November 20th. The stock was acquired at an average cost of $15.00 per share, with a total value of $30,000.00. Following the purchase, the chief financial officer now owns 2,000 shares of the company’s stock, valued at approximately $30,000. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 15,000 shares of company stock valued at $228,780. 30.20% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Janus Henderson Group PLC acquired a new stake in Diplomat Pharmacy in the second quarter valued at approximately $67,476,000. Cortina Asset Management LLC raised its holdings in Diplomat Pharmacy by 538.8% in the third quarter. Cortina Asset Management LLC now owns 1,616,792 shares of the company’s stock valued at $33,484,000 after acquiring an additional 1,363,696 shares in the last quarter. Northern Trust Corp raised its holdings in Diplomat Pharmacy by 95.1% in the second quarter. Northern Trust Corp now owns 1,234,477 shares of the company’s stock valued at $18,270,000 after acquiring an additional 601,834 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Diplomat Pharmacy by 149.7% in the third quarter. Dimensional Fund Advisors LP now owns 894,669 shares of the company’s stock valued at $18,528,000 after acquiring an additional 536,412 shares in the last quarter. Finally, Point72 Asset Management L.P. acquired a new stake in Diplomat Pharmacy in the third quarter valued at approximately $8,226,000. 72.48% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This article was first posted by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2017/12/15/brokerages-expect-diplomat-pharmacy-inc-dplo-will-post-quarterly-sales-of-1-17-billion.html.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Get a free copy of the Zacks research report on Diplomat Pharmacy (DPLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.